Cargando…

Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment

In this work, lipid-based nanoparticles (LBNP) were designed to combine tyrosine kinase inhibitor (TKI) Lapatinib (LAPA) with siRNA directed against apoptosis inhibitor protein Survivin (siSurvivin) in an injectable form. This nanosystem is based on lipid nanocapsules (LNCs) coated with a cationic p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eljack, Sahar, David, Stephanie, Chourpa, Igor, Faggad, Areeg, Allard-Vannier, Emilie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784347/ https://www.ncbi.nlm.nih.gov/pubmed/36558904 http://dx.doi.org/10.3390/ph15121452

Ejemplares similares

Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells
por: Eljack, Sahar, et al.
Publicado: (2022)

Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal
por: Eljack, Sahar, et al.
Publicado: (2022)

In vitro synergistic activity of cisplatin and EGFR-targeted nanomedicine of anti-Bcl-xL siRNA in a non-small lung cancer cell line model()
por: Nguyen, Phuoc Vinh, et al.
Publicado: (2022)

Anti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo
por: Wang, Xiaoli, et al.
Publicado: (2018)

Application of quantum dots as vectors in targeted survivin gene siRNA delivery
por: Zhao, Jianjiang, et al.
Publicado: (2013)

Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells
por: KUNZE, DOREEN, et al.
Publicado: (2012)

Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes
por: Alric, Christophe, et al.
Publicado: (2018)

Model Affitin and PEG modifications onto siRNA lipid nanocapsules: cell uptake and in vivo biodistribution improvements
por: Resnier, Pauline, et al.
Publicado: (2019)

Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
por: Bi, Ye, et al.
Publicado: (2018)

Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells
por: Basha, Genc, et al.
Publicado: (2011)

Advances in Lipid Nanoparticles for siRNA Delivery
por: Tam, Yuen Yi C., et al.
Publicado: (2013)

Effect of the amount of cationic lipid used to complex siRNA on the cytotoxicity and proinflammatory activity of siRNA-solid lipid nanoparticles
por: Hanafy, Mahmoud S., et al.
Publicado: (2023)

Downregulation of survivin by siRNA inhibits invasion and promotes apoptosis in neuroblastoma SH-SY5Y cells
por: Zhang, L., et al.
Publicado: (2014)

Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis
por: Sun, Ping, et al.
Publicado: (2016)

Development of a Combined Lipid-Based Nanoparticle Formulation for Enhanced siRNA Delivery to Vascular Endothelial Cells
por: He, Yutong, et al.
Publicado: (2022)

GL67 lipid-based liposomal formulation for efficient siRNA delivery into human lung cancer cells
por: Jarallah, Somayah J., et al.
Publicado: (2023)

Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells
por: Lehman, Christine E., et al.
Publicado: (2019)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer
por: Dinis Ano Bom, Ana Paula, et al.
Publicado: (2019)

Clinicopathological profile and management of thyroid carcinoma: a Sub-Saharan country experience
por: Elhassan, Moawia Mohammed Ali, et al.
Publicado: (2023)

Design and Validation of Nanofibers Made of Self-Assembled Peptides to Become Multifunctional Stimuli-Sensitive Nanovectors of Anticancer Drug Doxorubicin
por: Del Genio, Valentina, et al.
Publicado: (2022)

Radiolabeling, Quality Control and In Vivo Imaging of Multimodal Targeted Nanomedicines
por: Nguyen, Phuoc-Vinh, et al.
Publicado: (2022)

Transarterial chemoembolization of hepatocellular carcinoma in a rat model: the effect of additional injection of survivin siRNA to the treatment protocol
por: Vogl, Thomas J., et al.
Publicado: (2016)

Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer
por: Liu, Hong Yan, et al.
Publicado: (2016)

Therapeutic siRNA for drug-resistant HER2-positive breast cancer
por: Gu, Shenda, et al.
Publicado: (2016)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Survival Outcomes of Breast Cancer in Sudanese Women: A Hospital-Based Study
por: Muddather, Hiba F., et al.
Publicado: (2021)

Relapse-free survival in Sudanese women with non-metastatic breast cancer
por: Muddather, Hiba Faroug, et al.
Publicado: (2022)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants
por: Verma, Sharad, et al.
Publicado: (2018)

Nanoparticle Formulations of siRNA: The Next Generation of Targeted Therapy for Lymphomas and Leukemias?
por: Wang, Andrew Z.
Publicado: (2014)

Systematic Comparisons of Formulations of Linear Oligolysine Peptides with siRNA and Plasmid DNA
por: Kwok, Albert, et al.
Publicado: (2016)

Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma
por: Kundu, Anup K., et al.
Publicado: (2017)

Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations
por: Mandal, Abhirup, et al.
Publicado: (2020)

Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases
por: Kedinger, Valerie, et al.
Publicado: (2013)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases
por: Kalita, Tutu, et al.
Publicado: (2022)

In silico prediction of siRNA ionizable-lipid nanoparticles In vivo efficacy: Machine learning modeling based on formulation and molecular descriptors
por: Metwally, Abdelkader A., et al.
Publicado: (2022)

Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection
por: Supramaniam, Aroon, et al.
Publicado: (2023)

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months’ Remission with Lapatinib plus Capecitabine
por: Mailliez, Audrey, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n6knrnenjejs2h77kc42lk7cbr